CAR T-Cell therapy saves leukemia patient in China

Share This Post

Feb 2022: A 12-year-old girl from southwest China’s Chongqing Municipality was saved by an unconventional therapy instead of chemotherapy or hematopoietic stem cell transplantation.
Yi Mengdie has a seven-month medical history and has been given first-aid six times within a day due to the deterioration of her disease, according to local media (cbg.cn). She has acute lymphoblastic leukaemia (ALL), a type of cancer in which the bone marrow produces too many immature white blood cells.
Yi’s fever had gone away and her different indexes had returned to normal when CBG reporter saw her in the city’s Southwest Hospital in October after taking a new therapy called CAR-T cell therapy on September 18.

According to the same study, 25 individuals were treated in the hospital with this therapy.

CAR-T cells and TCR T cells have specific receptors on their surfaces that have been designed. They’re then expanded in the lab before being given back to the patient. 

According to the National Cancer Institute (NCI), the US government’s premier office for cancer research, T cells are commonly referred to as the immune system’s workhorses because of their vital function in coordinating the immune response and killing cells infected by infections.

Drawing blood from patients and extracting T cells is required for CAR-T cell treatment. The T cells are then genetically altered to develop receptors on their surface called chimeric antigen receptors (CARs), which allow the T cells to recognize and adhere to a specific protein, or antigen, on tumour cells, using a disarmed virus, according to the National Cancer Institute.

After the T cells have been designed to express the antigen-specific CAR, they are “expanded” into hundreds of millions in the laboratory.

If all goes according to plan, the designed cells will multiply in the patient’s body and, with the help of their engineered receptor, will recognize and kill cancer cells with the antigen on their surfaces, according to the NCI.

Renier J. Brentjens, an early leader in the CAR-T cell field, described CAR-T cells as “offering patients a living medication.”

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy